US-based software developer Cytel has expanded its operations into the Asia-Pacific region (APAC), so that companies in the area have easier access to its biometrics solutions.
Cytel has also successfully supported sponsors in all aspects of innovative clinical trials, from statistical design to implementation and regulatory acceptance, helping them reduce costs, shorten timelines, and better unlock the value of their data.
The ability to deliver advanced statistical analytics services to APAC is the result of a multi-stage expansion. This began in 2020, when Cytel acquired Laiya Consulting, a China-based specialist in Bayesian trial design. Subsequently, Cytel acquired a team of experienced Singapore-based biometrics experts with a suite of capabilities including management of independent Data Monitoring Committees.
The market is at the point where we need the use of advanced biostatistics and real-world capabilities like those honed at Cytel
In April 2022, Cytel began to establish an entity in Australia, with the arrival of Executive Strategic Consultant, James Matcham, who has more than 35 years’ experience of innovation in the largest biotech and pharma companies. The team in APAC has since then supported different phases of trials, in COVID-19, oncology, neurology, rare diseases, and others.
Matcham continued: "But APAC-based developers’ efforts to adopt trial-optimising innovation have been stifled by the services currently on offer in the region — namely CROs with only regional reach or global CROs without specialised analytics knowledge. Cytel offers both a rich global network and decades of advanced analytics know-how — precisely what’s needed to help APAC customers execute advanced clinical trial designs, better foresee roadblocks, and get their products registered in regions beyond APAC."
"There have been a number of advances in clinical research methods across APAC," said Jing Ping Yeo, Vice President and Head of APAC at Cytel. "The market is at the point where we need the use of advanced biostatistics and real-world capabilities like those honed at Cytel. Combined with the power of Cytel's trial design, simulation, and forecasting tools, this will have the potential to generate transformative collaboration and allow new medical assets developed in Asia to get to patients faster."
